tirzepatide diabetes trial Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Tirzepatide: First Approval | Drugs

Key Takeaways Stopping GLP-1 medications can make maintenance harder because hunger increases, fullness signals decrease, and calorie needs drop at a lower weight

Diabetes 56, 11071112 (2007)

Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis

Lower price = higher accessibility = massive demand unlock What changes: From premium product mass adoption From limited patients millions of users From niche market scalable opportunity Winners: Generic pharma players Distribution networks Volume-driven businesses But reality check: Only a few brands will dominate Execution (doctor network + supply chain) is key Pricing power shifts from innovator volume players Market insight: When barriers drop, demand doesnt increase linearly it explodes